Market Dashboard

Snapshot View

Interactive Charts

Latest Market Commentary

Market Commentary February 17th, 2025

Feb 17, 2025

Week in Review... Major market indices closed the week on a positive note, driven by robust data on the economic front, as the economy remains resilient despite trade and policy uncertainty. The S&P 500 rose +1.47%. The Dow Jones Industrial Average inched...

Market Commentary | February 10th, 2025

Feb 10, 2025

Week in Review... Major market indices ended the week lower due to mixed economic data. For the week ending February 7, 2025: The S&P 500 closed down -0.24%. The Dow Jones Industrial Average was lower, down -0.54% The tech-heavy Nasdaq fell to -0.53% The 10-Year...

Market Commentary | February 3rd, 2025

Feb 3, 2025

Week in Review... Major market indices experienced a volatile week driven by a combination of earnings releases, new entrants into the artificial intelligence sector, and the Federal Reserve’s rate decision. For the week ending January 31, 2025: The S&P 500 ended...

Market Commentary | January 27th, 2025

Jan 27, 2025

Week in Review... As the new president took office this past week, headlines were dominated by the potential impact of campaign promises turning into executive actions. The S&P 500 ended up 1.74% The Dow Jones Industrial Average led major indices up 2.15% The...

« Older Entries

Latest Market News from Around the Web

Personal Finance

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
February 21, 2025
The FDA's decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
UnitedHealth's rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
February 21, 2025
It extends a tumultuous period for UnitedHealth marked by the killing of a top executive, a costly cyberattack against its subsidiary and high medical costs.
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
February 21, 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Yankees throw out one of baseball's most notorious traditions: Players can now grow beards
February 21, 2025
For the first time in nearly 50 years, the New York Yankees are allowing players to grow "well-groomed beards."

Investment

Highlights of Warren Buffett's annual letter: Advice for Trump, 60 years at Berkshire helm
February 22, 2025
Warren Buffett opined on a wide range of topics in his much-anticipated annual letter to shareholders, including the U.S. fiscal problems and advice for Trump.
Warren Buffett amasses more cash and sells more stock, but doesn't explain why in annual letter
February 22, 2025
"The great majority of your money remains in equities," Buffett wrote in his highly-anticipated annual letter. "That preference won't change."
Activist ValueAct spots an overlooked opportunity at Liberty Live Group. How the move might pay off
February 22, 2025
Liberty Live represents Liberty Media Group’s ownership stake in Live Nation. The stock trades at a sharp discount to the entertainment and ticketing giant.
StockStory: A volatile tech stock worth owning for the long-term because of its dominance of a niche area
February 22, 2025
The analysts at StockStory breakdown TradeDesk.

Stock Market

Stocks making the biggest moves midday: UnitedHealth, Alibaba, Hims & Hers Health, Celsius and more
February 21, 2025
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest moves premarket: UnitedHealth, Rivian, Block, Celsius and more
February 21, 2025
These are the stocks posting the largest moves in premarket trading.
Stocks making the biggest moves after hours: Celsius, Dropbox, Block and more
February 20, 2025
See which stocks are posting big moves after the bell.
Stocks making the biggest midday moves: Palantir, AppLovin, Shake Shack, Walmart and more
February 20, 2025
These are some of the stocks posting the largest moves in midday trading.

Useful Resources & Links

Check the background of investment professionals on FINRA’s BrokerCheck.

Securities offered through Registered Representatives of Cambridge Investment Research, Inc., a broker-dealer, member FINRA/SIPC. Advisory services through Cambridge Investment Research Advisors, Inc., a Registered Investment Advisor. Cambridge and River City Financial are not affiliated. This communication is strictly intended for individuals residing in the states of AL, FL, KY, ME, NC, NJ, OH, SC, TX, VA, WA, WI and WV. No offers may be made or accepted from any resident outside the specific states referenced.

Cambridge’s Form CRS (Customer Relationship Summary)

The information being provided is strictly as a courtesy. When you link to any of these websites provided herein, River City Financial makes no representation as to the completeness or accuracy of information provided at these sites. Nor is the company liable for any direct or indirect technical or system issues or any consequences arising out of your access to or your use of third-party technologies, sites, information, and programs made available through this site.

River City Financial